Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty
  • Diagnostic Medicine chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • NGS & Genomic Profiling chevron_right
  • Prenatal Screening chevron_right
  • Specialty Program
  • Fabry Disease chevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • NGS & Genomic Profiling chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Genomic Profiling chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Fabry Disease chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Specialtieschevron_right
      • chevron_leftTopics
      • Arthritis
      • Biologics
      • Cancer
      • Cardiology
      • Dermatology
      • Diabetes
      • Diagnostic Medicine
      • MAC Lung Disease
      • Prenatal Screening
      • Primary Care
    • Submit A Question
    close

    Rodrigo Dienstmann, MD

    Rodrigo Dienstmann, MD

    Principal Investigator, Oncology Data Science (ODysSey) Group
    Vall d'Hebron Institute of Oncology
    Barcelona, Spain
    Computational Oncology Group
    Sage Bionetworks
    Seattle, Washington, USA


    Related Videos

    Based on the GENIE Consortium Project, what percentage of patients is estimated to be eligible for targeted therapy within the framework of precision cancer medicine, when evaluated with NGS? Video

    Based on the GENIE Consortium Project, what percentage of patients is estimated to be eligible for targeted therapy within the framework of precision cancer medicine, when evaluated with NGS?

    Based on the results of the GENIE Consortium Project, what percentage of patients is estimated to be eligible for targeted therapy within the framework of precision cancer medicine, when evaluated with NGS?

    What are the translational implications for NGS as you understand it from the results of the AACR/MSK GENIE Consortium project recently reported in Cancer Discovery? Video

    What are the translational implications for NGS as you understand it from the results of the AACR/MSK GENIE Consortium project recently reported in Cancer Discovery?

    What are the translational implications for NGS as you understand it from the results of the AACR/MSK GENIE Consortium project recently reported in Cancer Discovery?

    What have we learned from the GENIE Consortium Project about discrepancies between mutational profiles identified in the TCGA database versus those identified by NGS in the GENIE project? Video

    What have we learned from the GENIE Consortium Project about discrepancies between mutational profiles identified in the TCGA database versus those identified by NGS in the GENIE project?

    What have we learned from the GENIE Consortium Project about discrepancies between mutational profiles identified in primary tumors comprising the TCGA database versus those observed in distributions identified by NGS in the GENIE project ...

    What is the role of NGS, and role of fusion detection, in particular, in wild type EGFR NSCLC, non-squamous head and neck cancer, and glioblastoma? Video

    What is the role of NGS, and role of fusion detection, in particular, in wild type EGFR NSCLC, non-squamous head and neck cancer, and glioblastoma?

    What is the role of NGS, and role of fusion detection, in particular, in wild type EGFR NSCLC, non-squamous head and neck cancer, and glioblastoma?

    How is NGS altering our understanding of the importance of combining, aggregating, and analyzing a full range of genomic data to guide therapeutic decisions, especially in rare tumor types? Video

    How is NGS altering our understanding of the importance of combining, aggregating, and analyzing a full range of genomic data to guide therapeutic decisions, especially in rare tumor types?

    How is NGS altering our understanding of the importance of combining, aggregating, and analyzing a full range of genomic data — from single mutations and alterations to fusion genes, copy number and RNA expression data — to guide therapeutic ...

    Considering the relationship between total mutational burden and responsiveness to immune checkpoint inhibition, how will hybrid capture-based whole exome NGS guide precision-based treatment? Video

    Considering the relationship between total mutational burden and responsiveness to immune checkpoint inhibition, how will hybrid capture-based whole exome NGS guide precision-based treatment?

    In light of increasing evidence suggesting a relationship between total mutational burden and responsiveness to immune checkpoint inhibition, how are you positioning the role of hybrid capture-based whole exome NGS to guide precision-based cancer treatment?

    What is the evolving role of NGS in identifying targeted therapies in the setting of metastatic colorectal cancer, with a focus on BRAF mutations, HER2 amplification testing, and detection of microsatellite instability (MSI)? Video

    What is the evolving role of NGS in identifying targeted therapies in the setting of metastatic colorectal cancer, with a focus on BRAF mutations, HER2 amplification testing, and detection of microsatellite instability (MSI)?

    What is the evolving role of NGS in identifying targeted therapies in the setting of metastatic colorectal cancer? Can you discuss this with a focus on BRAF mutations, HER2 amplification testing, and detection of microsatellite instability ...

    In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do studies using BRAF V600 to guide vemurafenib and cetuximab in colorectal cancer show? (English) Video

    In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do studies using BRAF V600 to guide vemurafenib and cetuximab in colorectal cancer show? (English)

    In what kinds of non-melanoma cancers does BRAF V600 appear to be a targetable oncogene? What do initial studies using BRAF V600 to guide vemurafenib and cetuximab in patients with colorectal cancer show? Can genomic profiling updates ...

    Can targeted therapies based on NGS-based genomic alterations be employed after first-line failure? Are targeted, matched therapies late in a disease as successful as at time of presentation? (English) Video

    Can targeted therapies based on NGS-based genomic alterations be employed after first-line failure? Are targeted, matched therapies late in a disease as successful as at time of presentation? (English)

    Can targeted therapies based on NGS-based genomic alterations still be employed even after a patient has failed a first-line therapy? Are targeted, matched therapies late in the natural history of a patient’s disease as successful as using ...

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by the BroadcastMed Network